Skip to main content
main-content
Erschienen in: MMW - Fortschritte der Medizin 7/2017

04.12.2017 | Reizdarmsyndrom

Therapeutische Modulation der Darmmikrobiota beim Reizdarmsyndrom

Von Probiotika bis zur fäkalen Mikrobiota-Therapie

verfasst von: Prof. Dr. med. habil. P. C. Konturek, Prof. Dr. med. Yurdagül Zopf

Erschienen in: MMW - Fortschritte der Medizin | Sonderheft 7/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Eine gestörte Darmmikrobiota (Dysbiose) spielt eine zentrale Rolle in der Pathogenese funktioneller Darmerkrankungen, insbesondere des Reizdarmsyndroms.

Methode

In der Übersichtsarbeit sind vier derzeitige Optionen zur Behandlung des Reizdarmsyndroms dargestellt, die über eine Modulation der Darmmikrobiota wirken.

Ergebnisse und Schlussfolgerungen

Probiotika wirken sehr unterschiedlich auf die einzelnen Symptome des Reizdarms. Die Wahl des geeigneten Präparats sollte sich deshalb nach den klinischen Symptomen richten. Rifaximin ist bei ausgewählten Patienten wirksam. Einige Patienten profitieren auch von der Wiederholung dieser Antibiotikatherapie. Eine FODMAP-reduzierte Diät hat in Studien eine signifikante Linderung der Reizdarmsymptome gezeigt. Die fäkale Mikrobiota-Therapie (FMT) ist eine vielversprechende Behandlungsmöglichkeit. Derzeit fehlen allerdings entsprechende placebokontrollierte Studien, um die engültige Wirksamkeit dieser Methode beurteilen zu können.
Literatur
1.
Zurück zum Zitat Konturek PC. Reizdarmsyndrom: Diagnostik und therapeutische Optionen. Internist Prax 2014; 54: 269–279. Konturek PC. Reizdarmsyndrom: Diagnostik und therapeutische Optionen. Internist Prax 2014; 54: 269–279.
2.
Zurück zum Zitat Keller J, Wedel T, Seidl H, et al. S3 guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM) to the definition, pathophysiology, diagnosis and treatment of intestinal motility. Z Gastroenterol 2011; 49(3): 374–390. CrossRefPubMed Keller J, Wedel T, Seidl H, et al. S3 guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM) to the definition, pathophysiology, diagnosis and treatment of intestinal motility. Z Gastroenterol 2011; 49(3): 374–390. CrossRefPubMed
3.
4.
Zurück zum Zitat Camilleri M. Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther 2015; 42(7): 818–828. CrossRefPubMedPubMedCentral Camilleri M. Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther 2015; 42(7): 818–828. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut 2016; 65(2): 330–339. CrossRefPubMed Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut 2016; 65(2): 330–339. CrossRefPubMed
6.
Zurück zum Zitat Li D, Wang P, Wang P, Hu X, Chen F. The gut microbiota: a treasure for human health. Biotechnol Adv 2016; 34(7): 1210–1224. CrossRefPubMed Li D, Wang P, Wang P, Hu X, Chen F. The gut microbiota: a treasure for human health. Biotechnol Adv 2016; 34(7): 1210–1224. CrossRefPubMed
7.
Zurück zum Zitat Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 2017; 20(2): 145–155. CrossRefPubMed Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 2017; 20(2): 145–155. CrossRefPubMed
8.
Zurück zum Zitat Konturek PC, Zopf Y. Gut microbiome and psyche: paradigm shift in the concept of brain-gut axis. MMWFortschr Med 2016; 158(S4): 12–16. Konturek PC, Zopf Y. Gut microbiome and psyche: paradigm shift in the concept of brain-gut axis. MMWFortschr Med 2016; 158(S4): 12–16.
9.
Zurück zum Zitat Schroeder BO, Bäckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 2016; 22(10): 1079–1089. CrossRefPubMed Schroeder BO, Bäckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 2016; 22(10): 1079–1089. CrossRefPubMed
10.
Zurück zum Zitat Konturek PC, Brzozowski T, Burnat G, et al. Role of brain-gut axis in healing of gastric ulcers. J Physiol Pharmacol 2004; 55(1 Pt 2): 179–192. PubMed Konturek PC, Brzozowski T, Burnat G, et al. Role of brain-gut axis in healing of gastric ulcers. J Physiol Pharmacol 2004; 55(1 Pt 2): 179–192. PubMed
11.
Zurück zum Zitat Hyland NP, Cryan JF. Microbe-host interactions: Influence of the gut microbiota on the enteric nervous system. Dev Biol 2016; 417(2): 182–187. CrossRefPubMed Hyland NP, Cryan JF. Microbe-host interactions: Influence of the gut microbiota on the enteric nervous system. Dev Biol 2016; 417(2): 182–187. CrossRefPubMed
12.
Zurück zum Zitat Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? Neurochem Int 2016; 99: 110–132. CrossRefPubMed Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? Neurochem Int 2016; 99: 110–132. CrossRefPubMed
13.
Zurück zum Zitat Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6(5): 306–314. CrossRefPubMed Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6(5): 306–314. CrossRefPubMed
14.
Zurück zum Zitat Logan AC, Jacka FN, Prescott SL. Immune-microbiota interactions: dysbiosis as a global health issue. Curr Allergy Asthma Rep 2016; 16(2): 13. CrossRefPubMed Logan AC, Jacka FN, Prescott SL. Immune-microbiota interactions: dysbiosis as a global health issue. Curr Allergy Asthma Rep 2016; 16(2): 13. CrossRefPubMed
15.
Zurück zum Zitat Ringel Y, Ringel-Kulka T. The intestinal microbiota and irritable bowel syndrome. J Clin Gastroenterol 2015; 49 Suppl 1: S56–S59. CrossRefPubMed Ringel Y, Ringel-Kulka T. The intestinal microbiota and irritable bowel syndrome. J Clin Gastroenterol 2015; 49 Suppl 1: S56–S59. CrossRefPubMed
16.
Zurück zum Zitat Chung CS, Chang PF, Liao CH, et al. Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects. Scand J Gastroenterol 2016; 51(4): 410–419. CrossRefPubMed Chung CS, Chang PF, Liao CH, et al. Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects. Scand J Gastroenterol 2016; 51(4): 410–419. CrossRefPubMed
17.
Zurück zum Zitat Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017; 152(1): 111–123. CrossRefPubMed Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017; 152(1): 111–123. CrossRefPubMed
18.
Zurück zum Zitat Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 2013; 25(4): e272–e282. CrossRefPubMed Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 2013; 25(4): e272–e282. CrossRefPubMed
19.
Zurück zum Zitat Ahmad OF, Akbar A. Microbiome, antibiotics and irritable bowel syndrome. Br Med Bull 2016; 120(1): 91–99. CrossRefPubMed Ahmad OF, Akbar A. Microbiome, antibiotics and irritable bowel syndrome. Br Med Bull 2016; 120(1): 91–99. CrossRefPubMed
20.
Zurück zum Zitat Reid G. Probiotics: definition, scope and mechanisms of action. Best Pract Res Clin Gastroenterol 2016; 30(1): 17–25. CrossRefPubMed Reid G. Probiotics: definition, scope and mechanisms of action. Best Pract Res Clin Gastroenterol 2016; 30(1): 17–25. CrossRefPubMed
21.
Zurück zum Zitat Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol 2016; 22(32): 7186–7202. CrossRefPubMedPubMedCentral Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol 2016; 22(32): 7186–7202. CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Meier R. Probiotics in irritable bowel syndrome. Ann Nutr Metab 2010; 57 Suppl: 12–13. CrossRef Meier R. Probiotics in irritable bowel syndrome. Ann Nutr Metab 2010; 57 Suppl: 12–13. CrossRef
23.
Zurück zum Zitat Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109(10): 1547–1561. CrossRefPubMed Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109(10): 1547–1561. CrossRefPubMed
24.
Zurück zum Zitat Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol 2016; 16(1): 62. CrossRefPubMedPubMedCentral Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol 2016; 16(1): 62. CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res 2017; 61(1). Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res 2017; 61(1).
26.
Zurück zum Zitat Shokryazdan P, Faseleh Jahromi M, Navidshad B, Liang JB. Effects of prebiotics on immune system and cytokine expression. Med Microbiol Immunol 2017; 206(1): 1–9. CrossRefPubMed Shokryazdan P, Faseleh Jahromi M, Navidshad B, Liang JB. Effects of prebiotics on immune system and cytokine expression. Med Microbiol Immunol 2017; 206(1): 1–9. CrossRefPubMed
27.
Zurück zum Zitat Charalampopoulos D, Rastall RA. Prebiotics in foods. Curr Opin Biotechnol 2012; 23(2): 187–191. CrossRefPubMed Charalampopoulos D, Rastall RA. Prebiotics in foods. Curr Opin Biotechnol 2012; 23(2): 187–191. CrossRefPubMed
28.
Zurück zum Zitat Krumbeck JA, Maldonado-Gomez MX, Ramer-Tait AE, Hutkins RW. Prebiotics and synbiotics: dietary strategies for improving gut health. Curr Opin Gastroenterol 2016; 32(2): 110–119. CrossRefPubMed Krumbeck JA, Maldonado-Gomez MX, Ramer-Tait AE, Hutkins RW. Prebiotics and synbiotics: dietary strategies for improving gut health. Curr Opin Gastroenterol 2016; 32(2): 110–119. CrossRefPubMed
29.
Zurück zum Zitat Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Expert Opin Drug Saf 2016; 15(7): 983–991. CrossRefPubMed Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Expert Opin Drug Saf 2016; 15(7): 983–991. CrossRefPubMed
30.
Zurück zum Zitat Pimentel M, Lembo A, Chey WD, et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364(1): 22–32. CrossRefPubMed Pimentel M, Lembo A, Chey WD, et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364(1): 22–32. CrossRefPubMed
31.
Zurück zum Zitat Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016; 151(6): 1113–1121. CrossRefPubMed Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016; 151(6): 1113–1121. CrossRefPubMed
32.
Zurück zum Zitat Staudacher HM, Whelan K. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet. Proc Nutr Soc 2016; 75(3): 306–318. CrossRefPubMed Staudacher HM, Whelan K. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet. Proc Nutr Soc 2016; 75(3): 306–318. CrossRefPubMed
33.
Zurück zum Zitat Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 2014; 11(4): 256–266. CrossRefPubMed Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 2014; 11(4): 256–266. CrossRefPubMed
34.
Zurück zum Zitat Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146(1): 67–75. CrossRefPubMed Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146(1): 67–75. CrossRefPubMed
35.
Zurück zum Zitat Konturek PC, Haziri D, Brzozowski T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J Physiol Pharmacol 2015; 66(4): 483–491. PubMed Konturek PC, Haziri D, Brzozowski T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J Physiol Pharmacol 2015; 66(4): 483–491. PubMed
36.
Zurück zum Zitat Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014; 306(4): G310–G319. CrossRefPubMed Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014; 306(4): G310–G319. CrossRefPubMed
37.
Zurück zum Zitat Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65(5): 749–756. CrossRefPubMed Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65(5): 749–756. CrossRefPubMed
38.
Zurück zum Zitat van Nood E, Speelman P, Nieuwdorp M, Keller J. Fecal microbiota transplantation: facts and controversies. Curr Opin Gastroenterol 2014; 30(1): 34–39. CrossRefPubMed van Nood E, Speelman P, Nieuwdorp M, Keller J. Fecal microbiota transplantation: facts and controversies. Curr Opin Gastroenterol 2014; 30(1): 34–39. CrossRefPubMed
40.
41.
Zurück zum Zitat Borody TJ, George L, Andrews P, et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989; 150(10): 604. PubMed Borody TJ, George L, Andrews P, et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989; 150(10): 604. PubMed
Metadaten
Titel
Therapeutische Modulation der Darmmikrobiota beim Reizdarmsyndrom
Von Probiotika bis zur fäkalen Mikrobiota-Therapie
verfasst von
Prof. Dr. med. habil. P. C. Konturek
Prof. Dr. med. Yurdagül Zopf
Publikationsdatum
04.12.2017
Verlag
Springer Medizin
Schlagwort
Reizdarmsyndrom
Erschienen in
MMW - Fortschritte der Medizin / Ausgabe Sonderheft 7/2017
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI
https://doi.org/10.1007/s15006-017-0338-3

Der einfache Weg sich fortzubilden: Einführung zur Demenz

Ein Verbessertes Verständnis erleichtert den Umgang mit der Krankheit

Neu im Fachgebiet Allgemeinmedizin

01.07.2022 | Multiple Sklerose | Podcast | Nachrichten

Neues zum MS-Monitoring: Das können NFL-Biomarker

mit Prof. Dr. med. Tjalf Ziemssen, Experte für Multiple Sklerose

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Allgemeinmedizin und bleiben Sie gut informiert – ganz bequem per eMail.